| publication name | Anti‑vinculin antibodies as a novel biomarker in Egyptian patients with systemic sclerosis |
|---|---|
| Authors | Noha Hosni Ibrahim1 · Iman Mahmoud Fawzy2 · Tahany Mahmoud Gouda1 · Rasha Abdel Hameed El Sayed1 ·Maha Hosni Morsi3 · Al Shimaa Mohamed Sabry1 · Nashwa Ismail Hashaad1 |
| year | 2023 |
| keywords | |
| journal | |
| volume | Not Available |
| issue | Not Available |
| pages | Not Available |
| publisher | Not Available |
| Local/International | International |
| Paper Link | Not Available |
| Full paper | download |
| Supplementary materials | Not Available |
Abstract
Introduction Systemic sclerosis (SSc) is an autoimmune disorder that causes vasculopathy and scarring, most commonly in the lungs and skin, but it can also afect other organs. Endothelial vinculin plays a critical role in angiogenesis regulation. Therefore, vinculin overexpression in SSc may give rise to anti-vinculin antibodies, which may contribute to the development of SSc vasculopathy. The current research aims to (1) determine whether anti-vinculin autoantibodies play a signifcant role in the diagnosis of SSc and (2) compare anti-vinculin serum levels between two scleroderma patient populations, namely, pulmonary artery hypertension (PAH)–predominant and interstitial pulmonary fbrosis (IPF)–predominant groups. Methods This research included 140 participants categorized into three groups: group I—patients with PAH-predominant; group II—patients with ILD-predominant; group III—the control group. Anti-vinculin antibodies were detected in serum samples collected from all participants using ELISA. All subjects underwent high-resolution computed tomography (CT), difusing capacity for carbon monoxide, and pulmonary function tests. Results Patients in group I (PAH-predominant group, N=35) were 41.3 [±11.4] years old, with 80% being women. Patients in group II (ILD-predominant group, N=35) were 41.0 [±11.5] years old. The SSc group showed signifcantly higher antivinculin antibody levels than the control group (P